Interferon does not improve outcomes for hospitalized adults with COVID-19
Results of NIH clinical trial published today. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 18, 2021 Category: American Health Source Type: news

New report examines the rise of digital decentralised clinical trial technology
The market is forecast to reach $9.13 billion ( €7.84 billion) by 2026. (Source: mobihealthnews)
Source: mobihealthnews - October 18, 2021 Category: Information Technology Source Type: news

Cycling for health: Improving health and mitigating the climate crisis - Green S, Sakuls P, Levitt S.
OBJECTIVE: To review the literature about cycling and health, and to provide an overview and discussion of the available evidence. SOURCES OF INFORMATION: The MeSH terms bicycle and transportation were searched in PubMed. Clinical trials, practice reviews,... (Source: SafetyLit)
Source: SafetyLit - October 18, 2021 Category: International Medicine & Public Health Tags: Pedestrians and Bicycles Source Type: news

Use of commercial video games to improve postural balance in patients with multiple sclerosis:a systematic review and meta-analysis of randomised controlled clinical trials - Parra-Moreno M, Rodr íguez-Juan JJ, Ruiz-Cárdenas JD.
INTRODUCTION: Commercial video ga(me)((s are considered an effective tool to improve postural balance in different populations. Howe))(ver, t)(he effectivenes)s of these video games for patients with multiple sclerosis (MS) is unclear. OBJECTIVES: ... (Source: SafetyLit)
Source: SafetyLit - October 18, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Impact of users' attitudes toward anonymous internet interventions for cannabis vs. alcohol use: a secondary analysis of data from two clinical trials - Romero D, Johansson M, Hermansson U, Lindner P.
BACKGROUND: Numerous trials have demonstrated the efficacy of internet interventions targeting alcohol or cannabis use, yet a substantial proportion of users do not benefit from the format, warranting further research to identify moderators of treatment ef... (Source: SafetyLit)
Source: SafetyLit - October 16, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

A decade after gene therapy, children born with deadly immune disorder remain healthy
Over a decade ago, UCLA physician-scientists began using a pioneering gene therapy they developed to treat children born with a rare and deadly immune system disorder.They now report that the effects of the therapy appear to be long-lasting, with 90% of patients who received the treatment eight to 11 years ago still disease-free.ADA-SCID, oradenosine deaminase –deficient severe combined immunodeficiency, is caused by mutations in the gene that creates the ADA enzyme, which is essential to a functioning immune system. For babies with the disease, exposure to everyday germs can be fatal, and if untreated, most will die...
Source: UCLA Newsroom: Health Sciences - October 15, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., October 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &...
Source: Johnson and Johnson - October 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AMRA joins clinical trial on muscular dystrophy
AMRA Medical will be involved in the Facioscapulohumeral Muscular Dystroph...Read more on AuntMinnie.comRelated Reading: AMRA touts clinical trial results AMRA adds UK Biobank images to database AMRA teams up with National University of Singapore AMRA highlights body composition analysis research AMRA wins FDA clearance for MR software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 15, 2021 Category: Radiology Source Type: news

Pfizer vaccine booster: The most common side effect to expect - seen in 83% of recipients
THE PFIZER Covid vaccine is being offered as a booster shot to millions across the UK in a bid to suppress COVID-19 this winter. The pharmaceutical giant signed off its third dose after rigorously analysing data from clinical trials. Pfizer also listed the most common side effects to expect, with one trumping all others. (Source: Daily Express - Health)
Source: Daily Express - Health - October 15, 2021 Category: Consumer Health News Source Type: news

From depression to sleep, new era of psychiatric drugs is here, says startup CEO
Stanford psychiatrist's company has identified 11 drugs, including three already in mid-stage clinical trials, to more precisely target people with depression and PTSD. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 15, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
Today, the U.S. Food and Drug Administration announced it has awarded 11 new clinical trial research grants, equaling more than $25 million of funding over the next four years. The FDA's Congressionally-funded Orphan Products Grants Program awards these grants to clinical investigators to support the development of medical products for patients with rare diseases. (Source: World Pharma News)
Source: World Pharma News - October 14, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Researchers Open Phase I Clinical Trial of Cryoablation with Keytruda
Memorial Sloan Kettering Cancer Center in New York City has opened a novel clinical trial that combines the immunotherapy drug Keytruda with cryoablation for patients with unresectable malignant mesothelioma. The phase I trial opened in September and will be available at seven Memorial Sloan Kettering locations in the New York City/New Jersey area. Cryoablation, which is also known as cryotherapy or cryosurgery, is a treatment that freezes localized tumors with argon gas or liquid nitrogen. It has been used effectively with liver, kidney and prostate cancers, but its use with mesothelioma has been limited because of ...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Data from Federal Scientists Raise Questions About J. & J. Booster Shots
People who have received the company ’s one-shot vaccine may benefit from a booster with another brand. F.D.A. advisers will discuss the data on Friday. (Source: NYT Health)
Source: NYT Health - October 13, 2021 Category: Consumer Health News Authors: Carl Zimmer and Noah Weiland Tags: Vaccination and Immunization Coronavirus Delta Variant Coronavirus (2019-nCoV) Johnson & Pfizer Inc Clinical Trials Food and Drug Administration Moderna Inc Research United States Politics and Government National Institutes of Health Source Type: news

How my ivermectin research led to Twitter death threats | Dr Andrew Hill
I was sent images of coffins and hanged Nazi war criminals after finding medical fraud in clinical trialsThe story of online threats and abuse is very dark. In early 2021, my research team was analysing a new drug called ivermectin. In the first clinical trials, this drug seemed to prevent new infections and improve survival. When I first wrote about this, I started getting regular threats on Twitter, demanding that ivermectin should be approved worldwide and questioning the safety of vaccines.In March 2021, I received my first vaccine dose and posted a photo on Twitter from the clinic. Within minutes I was receiving stran...
Source: Guardian Unlimited Science - October 13, 2021 Category: Science Authors: Andrew Hill Tags: Coronavirus Vaccines and immunisation Infectious diseases Microbiology Medical research Science Health UK news Source Type: news

Pregnant women were kept out of clinical trials. That left them vulnerable to COVID-19
A long-standing tradition of keeping pregnant women out of clinical trials is having serious consequences with regard to COVID-19. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - October 13, 2021 Category: Science Authors: Amina Khan Source Type: news

Pregnant women were kept out of clinical trials. That left them vulnerable to COVID-19
A long-standing tradition of keeping pregnant women out of clinical trials is having serious consequences with regard to COVID-19. (Source: L.A. Times - Health)
Source: L.A. Times - Health - October 13, 2021 Category: Consumer Health News Authors: Amina Khan Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vacci...
Source: Roche Media News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vacci...
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news

Repurposed Drug Reverses Signs of Alzheimer's in Mice, Human Cells
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear. (Source: The Scientist)
Source: The Scientist - October 12, 2021 Category: Science Tags: News & Opinion Source Type: news

CureVac Withdraws Covid Vaccine Application in Europe
The German company will also terminate an advance purchase agreement with the European Commission for 405 million doses of the vaccine. (Source: NYT Health)
Source: NYT Health - October 12, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: Coronavirus (2019-nCoV) Clinical Trials Vaccination and Immunization RNA (Ribonucleic Acid) Regulation and Deregulation of Industry CureVac GmbH European Commission Source Type: news

Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose in those vaccinated with Covishield or Covaxin
Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

Ridge preservation in maxillary molar extraction sites with severe periodontitis: a prospective observational clinical trial
Published: 08 October Clinical Oral Investigations (2021)detailsAbstractObjectivesTo assess alveolar bone changes and treatment modality alterations after ridge preservation on maxillary molar extraction sockets with severe periodontitis, compared to natural healing.Material and methodsThirty-six maxillary infected-molar teeth either receiving ridge preservation (RG group) or undergoing natural healing (NT group) were investigated. Cone-beam computed tomography (CBCT) scanning was performed immediately after surgery (the baseline) and repeated 6 months later to measure the linear and volumetric changes of th...
Source: Dental Technology Blog - October 11, 2021 Category: Dentistry Source Type: news

Oral PTH Shows Promise for Osteoporosis in Early Phase 2 Study Oral PTH Shows Promise for Osteoporosis in Early Phase 2 Study
If the drug demonstrates safety and efficacy in a future phase 3 clinical trial, it could become the first oral bone-building (anabolic) therapy for osteoporosis, but it"s early days.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 11, 2021 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Patient and clinical factors associated with response to medications for posttraumatic stress disorder - Shiner BR, Gui J, Rozema L, Cornelius SL, Dufort V, Schnurr PP, Watts BV.
OBJECTIVE: Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have previously shown efficacy for posttraumatic stress disorder (PTSD) in randomized clinical trials. Two prior studies using Department of Veterans Affairs (VA) medical records da... (Source: SafetyLit)
Source: SafetyLit - October 11, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Black Patients Benefit Less From Ranibizumab Black Patients Benefit Less From Ranibizumab
Findings raise questions that highlight the lack of data on ethnicity in clinical trials of retina treatments.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

How Covid Vaccine Technology Could Improve Flu Vaccines
Vaccine makers are betting that the mRNA technology powering two successful Covid vaccines will help curb the tragic global death toll from the flu. (Source: NYT Health)
Source: NYT Health - October 9, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: Clinical Trials Vaccination and Immunization Influenza Coronavirus (2019-nCoV) RNA (Ribonucleic Acid) Research your-feed-science your-feed-healthcare Source Type: news

Precision medicine data dive shows water pill may be viable to test as Alzheimer ’s treatment
NIH-funded research reveals clinical trial candidate for those with genetic risk. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 8, 2021 Category: American Health Source Type: news

Alpha Tau gets FDA 'breakthrough' nod for brain tumor rad therapy
Alpha Tau Medical recently received a breakthrough device designation from th...Read more on AuntMinnie.comRelated Reading: Alpha Tau signs on Medison Canada as distributor Alpha Tau receives ISO certification Alpha Tau prepares clinical trials for Alpha DaRT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 8, 2021 Category: Radiology Source Type: news

The side effect seen 'more frequently' after Pfizer booster shot than previous doses - FDA
THE PFIZER vaccine is being offered as a booster shot to curb the threat of a resurgent coronavirus this winter. To support its emergency authorisation in the US, the Food and Drug Administration analysed data from the original clinical trial involving the booster shot. In its analysis, the FDA picked up a side effect "more frequently" seen after the booster dose. (Source: Daily Express - Health)
Source: Daily Express - Health - October 8, 2021 Category: Consumer Health News Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UK to Offer Extra COVID Shots to Trial Participants for Travel UK to Offer Extra COVID Shots to Trial Participants for Travel
Britain will offer additional COVID-19 shots to participants in clinical trials for coronavirus vaccines that have not yet been approved in order to let them travel, the health ministry said on Friday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR(TM) Presented as Late Breaking Trial at VIVA
The objective of this clinical investigation has been to eval... Devices, Interventional MedAlliance, SELUTION SLR, Sirolimus, Drug Eluting Balloon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2021 Category: Pharmaceuticals Source Type: news

Peninsula cell therapy company's stock sheds nearly 40% after-hours as FDA halts clinical trial
A single patient in the company's mid-stage clinical trial was found with a "chromosomal abnormality." (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 7, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Peninsula cell therapy company's stock sheds nearly 40% after-hours as FDA halts clinical trial
A single patient in the company's mid-stage clinical trial was found with a "chromosomal abnormality." (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 7, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula drug company regroups after failed study in deadly rare disease in kids
A drug from a small, ambitious Peninsula drug developer failed a clinical trial for an invariably fatal childhood genetic disease, but leaders of the company said they will regroup with the FDA to find a way to move the program forward. Retrotope Inc. said the late-stage study of its drug RT-001 failed to hit its main goal in infantile neuroaxonal dystrophy, or INAD, a rare condition which robs children of motor skills and voluntary muscle control and typically kills them before they turn 10. But… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 7, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Peninsula drug company regroups after failed study in deadly rare disease in kids
A drug from a small, ambitious Peninsula drug developer failed a clinical trial for an invariably fatal childhood genetic disease, but leaders of the company said they will regroup with the FDA to find a way to move the program forward. Retrotope Inc. said the late-stage study of its drug RT-001 failed to hit its main goal in infantile neuroaxonal dystrophy, or INAD, a rare condition which robs children of motor skills and voluntary muscle control and typically kills them before they turn 10. But… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 7, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Nanobiotix highlights ASTRO research studies
Nanobiotix will present results from clinical trials of its NBTXR3 radioenhance...Read more on AuntMinnie.comRelated Reading: ASTRO to require masks at October annual meeting PET/CT shows promise predicting outcomes in head, neck cancer ASTRO commits to October in-person annual meeting in Chicago RT + immunotherapy = head/neck cancer treatment option Nanobiotix plans head and neck cancer treatment trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2021 Category: Radiology Source Type: news

Metabolic care start-up Twin Health scores $140M and other digital health fundings
Also: Decentralized clinical trial platform Lightship raises $40 million, and digital pediatric clinic Brave Care scooped up $25 million. (Source: mobihealthnews)
Source: mobihealthnews - October 7, 2021 Category: Information Technology Source Type: news

Pfizer Asks F.D.A. to Authorize Its Covid-19 Vaccine for Children 5 to 11
The agency has promised to move quickly on the request and has tentatively scheduled a meeting at the end of the month to consider it. (Source: NYT Health)
Source: NYT Health - October 7, 2021 Category: Consumer Health News Authors: Sharon LaFraniere and Noah Weiland Tags: Pfizer Inc Food and Drug Administration Children and Childhood Coronavirus (2019-nCoV) Vaccination and Immunization Drugs (Pharmaceuticals) Clinical Trials Coronavirus Delta Variant Disease Rates Regulation and Deregulation of Industry Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC) - 11/18/2021 - 11/19/2021
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) and Center for Drug Evaluation and Research (CDER) welcome you to this FDA Virtual Public Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ECU joins clinical trial for Merck's Covid-19 pill
East Carolina University is part of a multi-center clinical trial that's testing the effectiveness of an antiviral pill made by Merck that could become a new weapon in the fight against Covid-19. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 7, 2021 Category: American Health Authors: Zac Ezzone Source Type: news

Volunteers needed for new clinical trial testing seasonal flu vaccine
Participants should be 65-85, healthy and have not received a flu shot this year. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - October 6, 2021 Category: Universities & Medical Training Tags: News Research Source Type: news

Upstate seeks volunteers for new clinical trial testing seasonal flu vaccine
Participants should be 65-85, healthy and have not received a flu shot this year. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - October 6, 2021 Category: Universities & Medical Training Tags: News Research Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Ro...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

GraphWear scores $20.5M for needle-free continuous glucose monitoring platform
The funding will help the company grow its team and go through clinical trials. (Source: mobihealthnews)
Source: mobihealthnews - October 5, 2021 Category: Information Technology Source Type: news

Gene therapy firm expands operations in RTP as headcount reaches 100
A gene therapy developer based in Research Triangle Park has expanded its operations as it prepares to move its programs into clinical trials. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 5, 2021 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news

Gene therapy firm expands operations in RTP as headcount reaches 100
A gene therapy developer based in Research Triangle Park has expanded its operations as it prepares to move its programs into clinical trials. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 5, 2021 Category: Biotechnology Authors: Zac Ezzone Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations ...
Source: Roche Investor Update - October 5, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations ...
Source: Roche Media News - October 5, 2021 Category: Pharmaceuticals Source Type: news